BioRestorative Therapies Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
BRTX
- Investments
-
1
- Share Price
-
$1.31
- (As of Thursday Closing)
BioRestorative Therapies General Information
Description
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Contact Information
Website
www.biorestorative.comCorporate Office
- 40 Marcus Drive
- Suite One
- Melville, NY 11747
- United States
Corporate Office
- 40 Marcus Drive
- Suite One
- Melville, NY 11747
- United States
BioRestorative Therapies Timeline
BioRestorative Therapies Stock Performance
As of 19-Nov-2026, BioRestorative Therapies’s stock price is $1.31. Its current market cap is $1.81M with 1.38M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.31 | $1.32 | $1.28 - $28.20 | $1.81M | 1.38M | 29.8K | -$21.40 |
BioRestorative Therapies Financials Summary
As of 31-Mar-2026, BioRestorative Therapies has a trailing 12-month revenue of $358K.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,994 | 5,954 | (3,136) | (3,836) |
| Revenue | 358 | 360 | 401 | 146 |
| EBITDA | (10,846) | (14,298) | (9,406) | (10,804) |
| Net Income | (11,057) | (14,242) | (8,979) | (10,418) |
| Total Assets | 4,640 | 4,080 | 12,280 | 12,612 |
| Total Debt | 0 | 0 | 0 | 162 |
BioRestorative Therapies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioRestorative Therapies Comparisons
Industry
Financing
Details
BioRestorative Therapies Competitors (11)
One of BioRestorative Therapies’s 11 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| DiscGenics | Venture Capital-Backed | Salt Lake City, UT | ||||
| FibroGenesis | Formerly Angel backed | Houston, TX | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Isto Biologics | Private Equity-Backed | Hopkinton, MA |
BioRestorative Therapies Patents
BioRestorative Therapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020265664-A1 | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same | Active | 29-Apr-2019 | ||
| AU-2020265664-B2 | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same | Active | 29-Apr-2019 | ||
| EP-3962501-A2 | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same | Active | 29-Apr-2019 | ||
| EP-3962501-A4 | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same | Active | 29-Apr-2019 | ||
| EP-3962501-B1 | Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same | Active | 29-Apr-2019 | A61K35/35 |
BioRestorative Therapies Signals
BioRestorative Therapies Acquisitions (1)
BioRestorative Therapies’s most recent deal was a Merger/Acquisition with Traxxec. The deal was made on 17-Apr-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Traxxec | 17-Apr-2009 | Merger/Acquisition | Other Containers and Packaging |
BioRestorative Therapies ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.39 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
BioRestorative Therapies FAQs
-
When was BioRestorative Therapies founded?
BioRestorative Therapies was founded in 1997.
-
Where is BioRestorative Therapies headquartered?
BioRestorative Therapies is headquartered in Melville, NY.
-
What is the size of BioRestorative Therapies?
BioRestorative Therapies has 14 total employees.
-
What industry is BioRestorative Therapies in?
BioRestorative Therapies’s primary industry is Biotechnology.
-
Is BioRestorative Therapies a private or public company?
BioRestorative Therapies is a Public company.
-
What is BioRestorative Therapies’s stock symbol?
The ticker symbol for BioRestorative Therapies is BRTX.
-
What is the current stock price of BioRestorative Therapies?
As of 19-Nov-2026 the stock price of BioRestorative Therapies is $1.31.
-
What is the current market cap of BioRestorative Therapies?
The current market capitalization of BioRestorative Therapies is $1.81M.
-
What is BioRestorative Therapies’s current revenue?
The trailing twelve month revenue for BioRestorative Therapies is $358K.
-
Who are BioRestorative Therapies’s competitors?
Mesoblast, DiscGenics, FibroGenesis, Regeneron Pharmaceuticals, and Isto Biologics are some of the 11 competitors of BioRestorative Therapies.
-
What is BioRestorative Therapies’s annual earnings per share (EPS)?
BioRestorative Therapies’s EPS for 12 months was -$21.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process